← Leaderboards
Elizabeth Gerstner
Massachusetts General Hospital
$2,756,329
Attributed
$5,120,321
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $880.6K · FY2014–25$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,120,321 · 4
By mechanism
R01$3,794,522 · 2
K23$896,400 · 1
R21$429,399 · 1
Top collaborators
- Priscilla Kaliopi Brastianos5 shared
- Scott Carter4 shared
- Bin Deng2 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Anand Viswanathan$12,542,460
- Ben Z Stanger$14,778,829
- Priscilla Kaliopi Brastianos$4,062,816
- Elyse R Park$12,238,672
- Karen L. Furie$5,939,373
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMagnetic Resonance ImagingResponseBlood VesselsBrainPatient PopulationChemotherapyPerfusionInsightTumor ProgressionImagePhysiologicalTreatment ResponseTissuesBiological MarkersPharmaceutical PreparationsBloodHeterogeneityBrain NeoplasmsMalignant NeoplasmsResistanceBiologicalImmune SystemClinical Trials
Grant awards (15)
Response assessment of glioblastoma using magnetic resonance elastography$195,181
R21 · FY2025 · CA
Using MRI and circulating tumor DNA to improve the interpretation of response to immunotherapy and targeted therapy in CNS metastases$646,356
R01 · FY2024 · CA · contact PI
Response assessment of glioblastoma using magnetic resonance elastography$234,218
R21 · FY2024 · CA
Using MRI and circulating tumor DNA to improve the interpretation of response to immunotherapy and targeted therapy in CNS metastases$666,767
R01 · FY2023 · CA · contact PI
Using MRI and circulating tumor DNA to improve the interpretation of response to immunotherapy and targeted therapy in CNS metastases$666,767
R01 · FY2022 · CA · contact PI
Using MRI and circulating tumor DNA to improve the interpretation of response to immunotherapy and targeted therapy in CNS metastases$694,319
R01 · FY2021 · CA · contact PI
Using MRI and circulating tumor DNA to improve the interpretation of response to immunotherapy and targeted therapy in CNS metastases$711,319
R01 · FY2020 · CA · contact PI
Evaluation of metastatic brain tumor heterogeneity and physiological response to immunotherapy using advanced MRI$159,655
R01 · FY2019 · CA · contact PI
Evaluation of impact of anti-VEGF drugs on concomitant chemotherapy in GBM$179,280
K23 · FY2018 · CA · contact PI
Evaluation of metastatic brain tumor heterogeneity and physiological response to immunotherapy using advanced MRI$141,236
R01 · FY2018 · CA · contact PI
Evaluation of impact of anti-VEGF drugs on concomitant chemotherapy in GBM$179,280
K23 · FY2017 · CA · contact PI
Evaluation of metastatic brain tumor heterogeneity and physiological response to immunotherapy using advanced MRI$108,103
R01 · FY2017 · CA · contact PI
Evaluation of impact of anti-VEGF drugs on concomitant chemotherapy in GBM$179,280
K23 · FY2016 · CA · contact PI
Evaluation of impact of anti-VEGF drugs on concomitant chemotherapy in GBM$179,280
K23 · FY2015 · CA · contact PI
Evaluation of impact of anti-VEGF drugs on concomitant chemotherapy in GBM$179,280
K23 · FY2014 · CA · contact PI